Arsanis, Inc. (ASNS) Declines to All-Time Low at $3.74 on Jun, 29

June 29, 2018 - By Edith Ladford

Arsanis, Inc. (NASDAQ:ASNS) reached all time low on Jun, 29 with $3.48 PT or 7.00 % below the last $3.74 share price. Barchart.com published the all time low. The company has $53.46M market cap. At $3.48 PT, the company’s valuation could be $3.74M less.

Ticker’s shares touched $3.74 during the last trading session after 6.50% change.Arsanis, Inc. is after having 0.00% since June 29, 2017. ASNS has 289,279 volume or 429.35% up from normal. The stock underperformed the S&P500 by 12.57%.

On August, 9 WallStreet anticipated Arsanis, Inc. (NASDAQ:ASNS)’s earnings release, according to RTT. Wall Street now forecasts 6.76 % negative EPS growth despite Arsanis, Inc. last quarter’s EPS of $-0.74.

For more Arsanis, Inc. (NASDAQ:ASNS) news announced briefly go to: Nasdaq.com, Streetinsider.com, Schaeffersresearch.com, Benzinga.com or Benzinga.com. The titles are as follows: “Mid-Morning Market Update: Markets Edge Lower; Walgreens Beats Q3 Views” announced on June 28, 2018, “Pre-Open Movers 06/28: (DRRX) (ZSAN) (CAVM) Higher; (ASNS) (PIR) (WBA) Lower (more…)” on June 28, 2018, “2 Healthcare Stocks Getting Buried; Option Bulls Cheer MRVL Spike” with a publish date: June 28, 2018, “24 Stocks Moving In Friday’s Pre-Market Session” and the last “50 Biggest Movers From Friday” with publication date: June 25, 2018.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address serious infectious diseases.The firm is valued at $53.46 million. The Company’s lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.Currently it has negative earnings. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis, Inc. (NASDAQ:ASNS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: